1. Home
  2. LPA vs DRUG Comparison

LPA vs DRUG Comparison

Compare LPA & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPA
  • DRUG
  • Stock Information
  • Founded
  • LPA 2013
  • DRUG 2019
  • Country
  • LPA United States
  • DRUG United States
  • Employees
  • LPA N/A
  • DRUG N/A
  • Industry
  • LPA
  • DRUG Pharmaceuticals and Biotechnology
  • Sector
  • LPA
  • DRUG Health Care
  • Exchange
  • LPA Nasdaq
  • DRUG Nasdaq
  • Market Cap
  • LPA 227.0M
  • DRUG 233.2M
  • IPO Year
  • LPA N/A
  • DRUG N/A
  • Fundamental
  • Price
  • LPA $6.70
  • DRUG $27.31
  • Analyst Decision
  • LPA
  • DRUG Strong Buy
  • Analyst Count
  • LPA 0
  • DRUG 6
  • Target Price
  • LPA N/A
  • DRUG $83.25
  • AVG Volume (30 Days)
  • LPA 34.8K
  • DRUG 19.9K
  • Earning Date
  • LPA 08-14-2025
  • DRUG 08-13-2025
  • Dividend Yield
  • LPA N/A
  • DRUG N/A
  • EPS Growth
  • LPA N/A
  • DRUG N/A
  • EPS
  • LPA 0.57
  • DRUG N/A
  • Revenue
  • LPA $45,218,701.00
  • DRUG N/A
  • Revenue This Year
  • LPA N/A
  • DRUG N/A
  • Revenue Next Year
  • LPA N/A
  • DRUG N/A
  • P/E Ratio
  • LPA $11.80
  • DRUG N/A
  • Revenue Growth
  • LPA 7.03
  • DRUG N/A
  • 52 Week Low
  • LPA $5.90
  • DRUG $0.93
  • 52 Week High
  • LPA $32.00
  • DRUG $79.02
  • Technical
  • Relative Strength Index (RSI)
  • LPA N/A
  • DRUG 41.95
  • Support Level
  • LPA N/A
  • DRUG $27.69
  • Resistance Level
  • LPA N/A
  • DRUG $28.74
  • Average True Range (ATR)
  • LPA 0.00
  • DRUG 1.29
  • MACD
  • LPA 0.00
  • DRUG 0.14
  • Stochastic Oscillator
  • LPA 0.00
  • DRUG 39.29

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: